Genetic and genomic approaches to identify and study the targets of bioactive small molecules

Chemistry and Biology

Volumn 11, Issue 5, 2004, Pages 609-618

  Zheng, Xiaofeng S ^a,c   Chan, Ting Fung ^a   Zhou, Heather H ^b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; DRUG RECEPTOR;

CHEMISTRY; DNA MICROARRAY; DRUG DESIGN; GENE EXPRESSION PROFILING; GENETICS; GENOME; GENOMICS; HUMAN; METABOLISM; METHODOLOGY; PROTEIN BINDING; PROTEOMICS; REVIEW;

BIOLOGICAL PRODUCTS; DRUG DESIGN; GENE EXPRESSION PROFILING; GENOME; GENOMICS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN BINDING; PROTEOMICS; RECEPTORS, DRUG;

EID: 2642573570     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2003.08.011     Document Type: Review

References (68)

1. Sehgal S. Sirolimus. its discovery, biological properties, and mechanism of action Transplant. Proc. 35:2003;S7-S14
2. Barbet N.C., Schneider U., Helliwell S.B., Stansfield I., Tuite M.F., Hall M.N. TOR controls translation initiation and early G1 progression in yeast. Mol. Biol. Cell. 7:1996;25-42
3. Zheng X.F., Schreiber S.L. Target of rapamycin proteins and their kinase activities are required for meiosis. Proc. Natl. Acad. Sci. USA. 94:1997;3070-3075
4. Hannun Y.A., Obeid L.M. The ceramide-centric universe of lipid mediated cell regulation. stress encounters of the lipid kind J. Biol. Chem. 277:2002;25847-25850
5. Liu J., Farmer J.D., Lane W.S., Friedman J., Weissman I., Schreiber S.L. Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell. 66:1991;807-815
6. Crabtree G.R. Calcium, calcineurin, and the control of transcription. J. Biol. Chem. 276:2001;2313-2316
7. Fruman D.A., Meyers R.E., Cantley L.C. Phosphoinositide kinases. Annu. Rev. Biochem. 67:1998;481-507
8. Schreiber S. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science. 287:2000;1964-1969
9. Stockwell B.R., Haggarty S.J., Schreiber S.L. High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications. Chem. Biol. 6:1999;71-83
10. Mayer T.U., Kapoor T.M., Haggarty S.J., King R.W., Schreiber S.L., Mitchison T.J. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science. 286:1999;971-974
11. Licitra E.J., Liu J.O. A three-hybrid system for detecting small ligand-protein receptor interactions. Proc. Natl. Acad. Sci. USA. 93:1996;12817-12821
12. Crews C.M., Splittgerber U. Chemical genetics. exploring and controlling cellular processes with chemical probes Trends Biochem. Sci. 24:1999;317-320
13. Stockwell B.R. Chemical genetics. ligand-based discovery of gene function Nat. Rev. Genet. 1:2000;116-125
14. Heitman J., Movva N.R., Hall M.N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 253:1991;905-909
15. Cafferkey R., Young P.R., McLaughlin M.M., Bergsma D.J., Koltin Y., Sathe G.M., Faucette L., Eng W.K., Johnson R.K., Livi G.P. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity. Mol. Cell. Biol. 13:1993;6012-6023
16. Kunz J., Henriquez R., Schneider U., Deuter-Reinhard M., Movva N.R., Hall M.N. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell. 73:1993;585-596
17. Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T., Lane W.S., Schreiber S.L. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 369:1994;756-758
18. Sabatini D.M., Erdjument-Bromage H., Lui M., Tempst P., Snyder S.H. RAFT1. a mammalian protein that binds to FKBP12 in a rapamycin dependent fashion and is homologous to yeast tors Cell. 78:1994;35-43
19. Zheng X.F., Florentino D., Chen J., Crabtree G.R., Schreiber S.L. TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin. Cell. 82:1995;121-130
20. Chen J., Zheng X.F., Brown E.J., Schreiber S.L. Identification of an 11-kDa FKBP12-rapamycin-binding domain within the 289-kDa FKBP12-rapamycin- associated protein and characterization of a critical serine residue. Proc. Natl. Acad. Sci. USA. 92:1995;4947-4951
21. Belanger A.E., Lai A., Brackman M.A., LeBlanc D.J. PCR-based ordered genomic libraries. a new approach to drug target identification for streptococcus pneumoniae Antimicrob. Agents Chemother. 46:2002;2507-2512
22. Sun Y., Taniguchi R., Tanoue D., Yamaji T., Takematsu H., Mori K., Fujita T., Kawasaki T., Kozutsumi Y. Sli2 (Ypk1), a homologue of mammalian protein kinase SGK, is a downstream kinase in the sphingolipid-mediated signaling pathway of yeast. Mol. Cell. Biol. 20:2000;4411-4419
23. Friant S., Lombardi R., Schmelzle T., Hall M.N., Riezman H. Sphingoid base signaling via Pkh kinases is required for endocytosis in yeast. EMBO J. 20:2001;6783-6792
24. Taunton J., Hassig C.A., Schreiber S.L. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science. 272:1996;408-411
25. Hassig C.A., Fleischer T.C., Billin A.N., Schreiber S.L., Ayer D.E. Histone deacetylase activity is required for full transcriptional repression by mSin3A. Cell. 89:1997;341-347
26. Wall M. Camptothecin and taxol. discovery to clinic Med. Res. Rev. 18:1998;299-314
27. Hsiang Y.H., Hertzberg R., Hecht S., Liu L.F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260:1985;14873-14878
28. Hsiang Y.H., Liu L.F. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 48:1988;1722-1726
29. Nitiss J., Wang J.C. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc. Natl. Acad. Sci. USA. 85:1988;7501-7505
30. Knab A.M., Fertala J., Bjornsti M.A. Mechanisms of camptothecin resistance in yeast DNA topoisomerase I mutants. J. Biol. Chem. 268:1993;22322-22330
31. Choi J., Chen J., Schreiber S.L., Clardy J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science. 273:1996;239-242
32. Brown E.J., Beal P.A., Keith C.T., Chen J., Shin T.B., Schreiber S.L. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature. 377:1995;441-446
33. Pelham H. Multiple targets for brefeldin A. Cell. 67:1991;449-451
34. Donaldson J.G., Finazzi D., Klausner R.D. Brefeldin A inhibits Golgi membrane-catalysed exchange of guanine nucleotide onto ARF protein. Nature. 360:1992;350-352
35. Helms J.B., Rothman J.E. Inhibition by brefeldin A of a Golgi membrane enzyme that catalyses exchange of guanine nucleotide bound to ARF. Nature. 360:1992;352-354
36. Peyroche A., Antonny B., Robineau S., Acker J., Cherfils J., Jackson C.L. Brefeldin A acts to stabilize an abortive ARF-GDP-Sec7 domain protein complex. involvement of specific residues of the Sec7 domain Mol. Cell. 3:1999;275-285
37. Chardin P., McCormick F. Brefeldin A. the advantage of being uncompetitive Cell. 97:1999;153-155
38. Kim D., Sarbassov D.D., Ali S., King J., Latek R., Erdjument-Bromage H., Tempst P., Sabatini D. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 110:2002;163-175
39. Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S., Tokunaga C., Avruch J., Yonezawa K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 110:2002;177-189
40. Hecht S. Bleomycin. new perspectives on the mechanism of action J. Nat. Prod. 63:2000;158-168
41. Hartwell L., Weinert T., Kadyk L., Garvik B. Cell cycle checkpoints, genomic integrity, and cancer. Cold Spring Harb. Symp. Quant. Biol. 59:1994;259-263
42. Campbell D.B., Nash H.A. Use of Drosophila mutants to distinguish among volatile general anesthetics. Proc. Natl. Acad. Sci. USA. 91:1994;2135-2139
43. Krishnan K.S., Nash H.A. A genetic study of the anesthetic response. mutants of Drosophila melanogaster altered in sensitivity to halothane Proc. Natl. Acad. Sci. USA. 87:1990;8632-8636
44. van-Swinderen B., Shook D.R., Ebert R.H., Cherkasova V.A., Johnson T.E., Shmookler-Reis R.J., Crowder C.M. Quantitative trait loci controlling halothane sensitivity in Caenorhabditis elegans. Proc. Natl. Acad. Sci. USA. 94:1997;8232-8237
45. van Swinderen B., Metz L.B., Shebester L.D., Mendel J.E., Sternberg P.W., Crowder C.M. Goalpha regulates volatile anesthetic action in Caenorhabditis elegans. Genetics. 158:2001;643-655
46. Choy R.K., Thomas J.H. Fluoxetine-resistant mutants in C. elegans define a novel family of transmembrane proteins. Mol. Cell. 4:1999;143-152
47. Kenerson H.L., Aicher L.D., True L.D., Yeung R.S. Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res. 62:2002;5645-5650
48. Langenbach R., Loftin C., Lee C., Tiano H. Cyclooxygenase knockout mice. models for elucidating isoform-specific functions Biochem. Pharmacol. 58:1999;1237-1246
49. Graef I.A., Chen F., Chen L., Kuo A., Crabtree G.R. Signals transduced by Ca(2+)/calcineurin and NFATc3/c4 pattern the developing vasculature. Cell. 105:2001;863-875
50. Dong L.Q., Zhang R.B., Langlais P., He H., Clark M., Zhu L., Liu F. Primary structure, tissue distribution, and expression of mouse phosphoinositide-dependent protein kinase-1, a protein kinase that phosphorylates and activates protein kinase Czeta. J. Biol. Chem. 274:1999;8117-8122
51. Bargmann, C.I. (2001). High-throughput reverse genetics: RNAi screens in Caenorhabditis elegans. Genome Biol 2, REVIEWS1005.1-1005.3.
52. Spradling A.C., Stern D., Beaton A., Rhem E.J., Laverty T., Mozden N., Misra S., Rubin G.M. The Berkeley Drosophila genome project gene disruption project. single P-element insertions mutating 25% of vital Drosophila genes Genetics. 153:1999;135-177
53. Giaever G., Shoemaker D.D., Jones T.W., Liang H., Winzeler E.A., Astromoff A., Davis R.W. Genomic profiling of drug sensitivities via induced haploinsufficiency. Nat. Genet. 21:1999;278-283
54. Coelho P.S., Kumar A., Snyder M. Genome-wide mutant collections. toolboxes for functional genomics Curr. Opin. Microbiol. 3:2000;309-315
55. Zheng X.F., Chan T.-F. Chemical genomics in the global study of protein functions. Drug Discov. Today. 7:2001;197-205
56. Zheng X.F., Chan T.-F. Chemical genomics. a systematic approach in biological research and drug discovery Curr. Issues Mol. Biol. 4:2001;33-43
57. Chan T.F., Carvalho J., Riles L., Zheng X.F.S. A chemical genomics approach toward understanding the global functions of TOR. Proc. Natl. Acad. Sci. USA. 97:2000;13227-13232
58. Xu C.W. High-density cell microarrays for parallel functional determinations. Genome Res. 12:2002;482-486
59. Shoemaker D.D., Lashkari D.A., Morris D., Mittmann M., Davis R.W. Quantitative phenotypic analysis of yeast deletion mutants using a highly parallel molecular bar-coding strategy. Nat. Genet. 14:1996;450-456
60. Lockhart D.J., Winzeler E.A. Genomics, gene expression and DNA arrays. Nature. 405:2000;827-836
61. Marton M.J., DeRisi J.L., Bennett H.A., Iyer V.R., Meyer M.R., Roberts C.J., Stoughton R., Burchard J., Slade D., Dai H., et al. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat. Med. 4:1998;1293-1301
62. Bernstein B.E., Tong J.K., Schreiber S.L. Genomewide studies of histone deacetylase function in yeast. Proc. Natl. Acad. Sci. USA. 97:2000;13708-13713
63. Butte A.J., Tamayo P., Slonim D., Golub T.R., Kohane I.S. Discovering functional relationships between RNA expression and chemotherapeutic susceptibility using relevance networks. Proc. Natl. Acad. Sci. USA. 97:2000;12182-12186
64. Graves P.R., Haystead T.A.J. Molecular biologist's guide to proteomics. Microbiol. Mol. Biol. Rev. 66:2002;39-63
65. MacBeath G., Schreiber S.L. Printing proteins as microarrays for high-throughput function determination. Science. 289:2000;1760-1763
66. Zhu H., Klemic J.F., Chang S., Bertone P., Casamayor A., Klemic K.G., Smith D., Gerstein M., Reed M.A., Snyder M. Analysis of yeast protein kinases using protein chips. Nat. Genet. 26:2000;283-289
67. Lueking A., Horn M., Eickhoff H., Bussow K., Lehrach H., Walter G. Protein microarrays for gene expression and antibody screening. Anal. Biochem. 270:1999;103-111
68. Weinberger S.R., Morris T.S., Pawlak M. Recent trends in protein biochip technology. Pharmacogenomics. 1:2000;395-416